Abstracts tagged "Biologic drugs"

Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Nick Bansback¹, Eric Fu², Daphne Guh², Huiying Sun², Wei Zhang², Diane Lacaille^3,4 and Aslam H. Anis¹, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].